Slingshot members are tracking this event:

Antares Pharma Announces Settlement of Patent Litigation for Key Alliance Business Product

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
High Medium Low
Impact on Stocks


Additional Information

Additional Relevant Details Teva Pharmaceuticals USA, Inc. has settled the patent litigation with AstraZeneca Pharmaceuticals LP, AstraZeneca AB and Amylin Pharmaceuticals, LLC (AstraZeneca) relating to AstraZeneca’s US Patent Nos. 6,858,576, 6,872,700, 6,956,026, 7,297,761, 6,902,744, 7,521,423, and 7,741,269 and AstraZeneca’s BYETTA® (exenatide), and entered into a settlement and license agreement with AstraZeneca, pursuant to which AstraZeneca granted a license to Teva to manufacture and commercialize the generic version of BYETTA® described in Teva’s ANDA No. 205984 in the United States. According to Teva, the settlement allows them to commercialize its generic version of BYETTA® (exenatide injection) in the U.S. beginning October 15, 
Slingshot Insights Explained
Catalyst Date
Occurred on:
Jun 23, 2016
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Patent Litigation, Byetta